Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen-Reference-Cited by-同舟云学术

Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen

Published:2003-11 Issue:5 Volume:39 Page:826-833
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Lunel Françoise,Veillon Pascal,Fouchard-Hubert Isabelle,Loustaud-Ratti Véronique,Abergel Armand,Silvain Christine,Rifflet Hervé,Blanchi Alain,Causse Xavier,Bacq Yannick,Payan Christopher

Publisher

Elsevier BV

Subject

Hepatology

Reference29 articles.

1. Pretreatment serum hepatitis C virus levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C;Martinot-Peignoux;Hepatology,1995

2. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks treatment of chronic infection with hepatitis C virus;Poynard;Lancet,1998

3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for treatment for chronic hepatitis C;McHutchison;N Engl J Med,1998

4. Consensus Statement;J Hepatol,1999

5. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples;Transfusion;2015-05-27

2. Hepatitis C core Ag and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow-up?;Reviews in Medical Virology;2011-11-24

3. Analytical Performance Characteristics and Clinical Utility of a Novel Assay for Total Hepatitis C Virus Core Antigen Quantification;Journal of Clinical Microbiology;2010-04

4. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay;Journal of Clinical Virology;2009-11

5. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy;Journal of Digestive Diseases;2009-02